Carlos V. Paya is the CEO of Vaxcyte, Inc., a growing biopharmaceutical company. He joined the company in late 2021 and quickly stepped up as a key figure on the Board of Directors, even taking on the role of Chair....
Carlos V. Paya is the CEO of Vaxcyte, Inc., a growing biopharmaceutical company. He joined the company in late 2021 and quickly stepped up as a key figure on the Board of Directors, even taking on the role of Chair. He is focused on aligning the company’s progress in vaccine development with solid performance metrics. His journey in this role has seen him lead through significant milestones, where the company's stock options have varied, reflecting the demand and performance of their projects. In 2023, his total compensation reached about 1.15 million USD, emphasizing the company's emphasis on performance-based pay. Notably, his options grant in that same year was structured with an exercise price of $41.67, showing confidence in the company's future value. Paya's commitment to effective governance is evident in his service on multiple board committees, demonstrating his hands-on approach in shaping the company's direction.